FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

Beckman Coulter Troponin Assay Cleared

FDA clears a Beckman Coulter Diagnostics 510(k) for its new high-sensitivity troponin assay, Access hsTnI, for use on the Access 2, DxI and all Access...

Human Drugs

Exela Pharma FDA-483

FDA releases an FDA-483 with five observations from a 2017 inspection at Exela Pharma Sciences, an outsourcing facility.

FDA General

Public Citizen Wants Uloric Taken Off Market

Public Citizen calls on FDA to order withdrawal of Takedas Uloric from the market due to what it says is an unacceptable risk of death.

Human Drugs

Revive Therapeutics Get Orphan Status for Cannabidiol

FDA grants Revive Therapeutics an orphan drug designation for cannabidiol for treating autoimmune hepatitis, a rare disease that causes inflammation t...

Federal Register

Info Collection Extension on State Enforcement Notifications

Federal Register notice: FDA files for OMB approval a proposed information extension for State Enforcement Notifications.

Human Drugs

GBT Sees Positive Results in Phase 3 Voxelotor Trial

Global Blood Therapeutics say it is in discussions with FDA about accelerated approval for its voxelotor to treat sickle cell anemia based on partial ...

Human Drugs

Priority Review for Jazz Xyrem sNDA

FDA accepts for priority review a Jazz Pharmaceuticals supplemental NDA seeking revised labeling for Xyrem (sodium oxybate) oral solution, to include ...

Human Drugs

FDA More Partner than Regulator: ProPublica

ProPublica explores the possibility that)user fees and industry support of doctors have led to FDA becoming more of an industry partner than a regulat...

Human Drugs

Achaogens Zemdri Approved for UTI; But 2nd Indication Rejected

FDA approves an Achaogen NDA for Zemdri (plazomicin) for adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by ...

Human Drugs

API Deviations at Henan Lihua Pharmaceutical

FDA warns Chinas Henan Lihua Pharmaceutical about significant deviations in its production of active pharmaceutical ingredients at two facilities.